Who is sponsoring NCT06542770?

NCT06542770 is sponsored by Parc de Salut Mar.

What drugs are being tested in NCT06542770?

Interventions in NCT06542770: Early implant of cardiac monitor.

What condition does NCT06542770 study?

NCT06542770 studies Paroxysmal Atrial Fibrillation, Cardiac Rhythm Disorder, Left Atrial Dilatation, Cryptogenic Stroke.

Is NCT06542770 still recruiting?

NCT06542770 is currently recruiting now. Last updated 2 August 2024.

Last reviewed 2024-08-02 · How we verify

NCT06542770: CRIPTO-FAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Subtle Ultrasound Atrial Anomalies Predicts the Early Diagnosis of Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Patients With Cryptogenic Stroke. A Randomized Trial

Recruiting now NA Last updated 2 August 2024

What this trial tests

NA trial testing Early implant of cardiac monitor in Paroxysmal Atrial Fibrillation in 100 participants. Currently enrolling.

Timeline

1 January 2021

Primary endpoint
1 September 2024

1 December 2024

Quick facts

Lead sponsor	Parc de Salut Mar
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	1 January 2021
Primary completion	1 September 2024
Estimated completion	1 December 2024
Sites	1 location across Spain

Drugs / interventions tested

Early implant of cardiac monitor

Conditions studied

Paroxysmal Atrial Fibrillation — all drugs for Paroxysmal Atrial Fibrillation →
Cardiac Rhythm Disorder — all drugs for Cardiac Rhythm Disorder →
Left Atrial Dilatation — all drugs for Left Atrial Dilatation →
Cryptogenic Stroke — all drugs for Cryptogenic Stroke →

Sponsor

Parc de Salut Mar — full company profile →

Who can join

Adults 50 to 89, any sex, with Paroxysmal Atrial Fibrillation or Cardiac Rhythm Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Detection atrial fibrilation at follow-up
Time frame: Up to 2 years follow-up (ICM and standard care practice)
defined by the presence of a confirmatory 12-leads ECG, or a registration lasting more than 30 seconds in, either the 72h-Holter-Monitoring, or in the ICM recording. In case of AF detection OAC was initiated immediately.

Sponsor's own description

Cryptogenic stroke (CS) causes about 30% of admissions to a stroke unit. Silent paroxysmal atrial fibrillation (PAF) is believed to be the underlying cause of a significant proportion of patients. The use of implantable cardiac monitors (ICM) early after the CS has demonstrated benefits in the diagnostic yield, but the indication for ICM in the current guidelines remains unclear. Atrial contraction strain (ACS) evaluated by cardiac ultrasound could be of help to select the patients more prone to suffer from silent PAF. The purpose of this investigation is to conduct a randomized prospective unicentric study to evaluate the usefulness of ICM for early detection of silent PAF episodes in patients with CS. Clinical and ultrasound predictors of PAF occurrence (ACS) will be studied in order to define patients needing a closer follow-up.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ultra-Early Continuous ECG Monitoring for Silent Atrial Fibrillation Diagnosis in Cryptogenic Stroke: The CRIPTOFAST Randomized Controlled Trial.
Vallès E, Garcia AB, Giralt-Steinhauer E, Ble M, et al · · 2026 · PMID 41480831 · DOI 10.1111/ene.70482

Verify or expand the search:

Other recruiting trials for Paroxysmal Atrial Fibrillation

Currently open trials in the same condition.

NCT07535268 — REPRESENT-PF Registry · recruiting
NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
NCT07281898 — Burst Stimulation for Paroxysmal Atrial Fibrillation · NA · recruiting
NCT07116525 — A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter · NA · recruiting
NCT06765356 — Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias · Phase 4 · active not recruiting

Other Parc de Salut Mar trials

Trials by the same sponsor.

NCT06163235 — Efficacy of a Mobile Application and Semi-attendance Program in Bariatric Surgery · NA · not yet recruiting
NCT07223450 — A Study on Oral and Intranasal Forms of Oxycodone in Healthy Volunteers Using Pharmacokinetic Modeling · Phase 1 · completed
NCT07504913 — Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41 · recruiting
NCT06806072 — BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY · NA · not yet recruiting
NCT04084795 — Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06542770 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Parc de Salut Mar
Last refreshed: 2 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06542770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing